However, the developers have yet to report Phase I results, which would show whether it is safe and whether or not it induces an immune response.
"The Lancet" medical journal has confirmed that it would be publishing early-stage human trial data from the Oxford team on Monday.
"We now know the Oxford vaccine covers both bases - it produces both a T-cell and an antibody response", an unnamed source told the Telegraph. We're working with the other potential vaccines around the world, in America and Germany and the Netherlands. It is also the only vaccine being developed in the country that has reached the human trials stage. She added that the participants in the clinical trial will be medically monitored after they are released on July 15 and July 20, according to Newsweek.
However any final conclusions about the immune response among the volunteers will be drawn by the Gamaleya Institute, which developed the vaccine, and are expected towards the end of the month. Oxford's phase 3 trial has several 8,000 subjects across the United Kingdom, and 6,000 in South Africa and Brazil for these areas are more prone to the infection of coronavirus.
By the end of this year, Russian Federation is preparing to make 30 million doses of its experimental coronavirus vaccine in the country.
White House officials raise questions about Fauci
Fauci has been an independent and outspoken voice for truth as the nation has struggled to fight the coronavirus pandemic". Others within the president's orbit chalk up the disagreement to understandable frustration on Trump's part.
A larger-scale trial, meant to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russian Federation in mid-August.
The Telegraph reported that hopes are high for the vaccine after it showed to develop a "double defence" against coronavirus.
Health Secretary Matt Hancock also said the "best case scenario" is a vaccine being made available some time this year but admitted it may be more likely to be in 2021.
Phase 2 of the trial began in May, and Phase 3 is due to launch this month. The first phase-I human trials started on June 18 with 18 volunteers from the armed forces constituting as group one, while the second group of 20 civilian volunteers were vaccinated on June 23.
"Virtually any vaccine inevitably does this", Danny Altmann, a professor of immunology at the Imperial College London, said, reported Guardian, referring to the generation of antibodies and T-cells.